Therapy Areas: Oncology
Jacabio reports pre-clinical data for JAB-23E73 pan-KRAS inhibitor at international conference
24 October 2025 - Chinese pharmaceutical company Jacobio Pharma (HK:1167) announced on Thursday the presentation of its internally discovered pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC In...
Orion secures exclusive commercial licence for Abzena cancer antibody
23 October 2025 - Finnish pharmaceutical company Orion Corporation (HEL:ORNBV) and Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced on Thursday that Orion has o...
FDA grants priority review for Merck's KEYTRUDA combinations with Padcev in muscle-invasive bladder cancer
23 October 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that the US Food and Drug Administration (FDA) has granted prio...
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
23 October 2025 - ACM Biolabs, a Singapore-based clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, on Wednesday reported encouraging early clinical fi...
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
22 October 2025 - American clinical-stage biopharmaceutical company Galera Therapeutics, Inc. (OTC: GRTX) announced on Wednesday that it has entered into an Asset Purchase Agreement with Toronto-based...
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
22 October 2025 - American biotech company Becton, Dickinson and Company (BD) (NYSE: BDX) announced on Wednesday a new self-collection solution for human papillomavirus (HPV) testing in markets outsid...